PTAFR and neoplasm: However, compared with the SKOV3 + WEB2086 group, the SKOV3 + MSC + WEB2086 group exhibited a significantly larger tumour volume (Fig. 5a), which indicated that the PAFR inhibitor could not completely block the tumour-promoting effect of MSCs.